0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Fas

Fas

Brief Information

Name:Apoptosis-mediating surface antigen FAS
Target Synonym:Tumor Necrosis Factor Receptor Superfamily, Member 6,Apo-1 antigen,CD95,APT1,FAS1,TNFRSF6,FAS,Fas Cell Surface Death Receptor,Fas (TNF Receptor Superfamily, Member 6),Apoptosis-Mediating Surface Antigen FAS,TNF Receptor Superfamily Member 6,FASLG Receptor,CD95 Antigen,Mutant Tumor Necrosis Receptor Superfamily Member 6,Tumor Necrosis Factor Receptor Superfamily Member 6,Apoptosis Signaling Receptor FAS,APO-1 Cell Surface Antigen,Apoptosis Antigen 1,Fas AMA,ALPS1A,APO-1,FASTM,fas Receptor
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
FAS-H5229 Human Human Fas / TNFRSF6 / CD95 Protein, His Tag (MALS verified)
FAS-H5229-structure
FAS-H5229-sds
FAS-H5252 Human Human Fas / TNFRSF6 / CD95 Protein, Fc Tag (MALS verified)
FAS-H5252-structure
FAS-H5252-sds
ACRO Quality

Part of Bioactivity data

FAS-H5229-MALS-HPLC
Fas MALS images

The purity of Human Fas, His Tag (Cat. No. FAS-H5229) is more than 85% and the molecular weight of this protein is around 24-34 kDa verified by SEC-MALS.

FAS-H5252-MALS-HPLC
Fas MALS images

The purity of Human Fas Protein, Fc Tag (Cat. No. FAS-H5252) is more than 90% and the molecular weight of this protein is around 93-110 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

FAS,ALPS1A,APO1,APT1,CD95,FAS1,FASTM,TNFRSF6,FasR

Background

The Fas is also known as FAS receptor (FasR), apoptosis antigen 1 (APO-1 or APT), cluster of differentiation 95 (CD95) or tumor necrosis factor receptor superfamily member 6 (TNFRSF6). is a death receptor on the surface of cells that leads to programmed cell death (apoptosis). It is one of two apoptosis pathways, the other being the mitochondrial pathway. FasR is located on chromosome 10 in humans and 19 in mice. Similar sequences related by evolution (orthologs) are found in most mammals. Fas forms the death-inducing signaling complex (DISC) upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent cell causes trimerization of Fas receptor. This event is also mimicked by binding of an agonistic Fas antibody, though some evidence suggests that the apoptotic signal induced by the antibody is unreliable in the study of Fas signaling. To this end, several clever ways of trimerizing the antibody for in vitro research have been employed.Upon ensuing death domain (DD) aggregation, the receptor complex is internalized via the cellular endosomal machinery. This allows the adaptor molecule FADD to bind the death domain of Fas through its own death domain. Recently, Fas has also been shown to promote tumor growth, since during tumor progression, it is frequently downregulated or cells are rendered apoptosis resistant. Cancer cells in general, regardless of their Fas apoptosis sensitivity, depend on constitutive activity of Fas. This is stimulated by cancer-produced Fas ligand for optimal growth.

Clinical and Translational Updates

Related Molecule

Fas Ligand

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Kanglaite Approved Zhejiang Kanglaite Pharmaceutical Co Ltd Kanglaite Mainland China Liver Neoplasms; Carcinoma, Non-Small-Cell Lung Zhejiang Kanglaite Pharmaceutical Co Ltd 1997-01-01 Liver Neoplasms; Solid tumours; Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Kanglaite Approved Zhejiang Kanglaite Pharmaceutical Co Ltd Kanglaite Mainland China Liver Neoplasms; Carcinoma, Non-Small-Cell Lung Zhejiang Kanglaite Pharmaceutical Co Ltd 1997-01-01 Liver Neoplasms; Solid tumours; Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ONL-1204 ONL-1204 Phase 2 Clinical Onl Therapeutics Glaucoma, Open-Angle; Retinal Detachment; Geographic Atrophy Details
ONL-1204 ONL-1204 Phase 2 Clinical Onl Therapeutics Glaucoma, Open-Angle; Retinal Detachment; Geographic Atrophy Details

This web search service is supported by Google Inc.

totop

Nachricht schicken